Table 2.
Main characters of recruited studies.
| Author | Reference | Country | Ethnicity | Sample size | Dose | Follow-up period | ||
|---|---|---|---|---|---|---|---|---|
| Combination treatment | Tamsulosin monotherapy | Combination treatment | Tamsulosin monotherapy | |||||
| Kerrebroeck b Philip (2013) | (Kerrebroeck et al., 2013) | Europe | Caucasian | 339 | 327 | T (0.4 mg) plus S (6 or 9 mg) | T (0.4 mg) | 12 weeks |
| Yuan (2017) | (Yuan et al., 2017) | China | Asian | 32 | 32 | T (0.2 mg) plus S (5 mg) | T (0.2 mg) | 4 weeks |
| Xiang (2012) | (Xianhe et al., 2012) | China | Asian | 20 | 20 | T (0.2 mg) plus S (5 mg) | T (0.2 mg) | 8 weeks |
| Liang (2012) | (Yan et al., 2012) | China | Asian | 55 | 53 | T (0.2 mg) plus S (5 mg) | T (0.2 mg) | 4 weeks |
| Song (2017) | (Song et al., 2016) | China | Asian | 51 | 76 | T (0.2 mg) plus S (5 mg) | T (0.2 mg) | 2 weeks |
| Xing (2016) | (Yongshi et al., 2016) | China | Asian | 48 | 41 | T (0.2 mg) plus S (5 mg) | T (0.2 mg) | 12 weeks |
| Duan (2018) | (Hao-ran et al., 2017) | China | Asian | 34 | 34 | T (0.2 mg) plus S (5 mg) | T (0.2 mg) | 12 weeks |
| Seo (2011) | (Seo et al., 2011) | Korea | Asian | 30 | 30 | T (0.2 mg) plus S (5 mg) | T (0.2 mg) | 3 months |
| Lee a Kyu (2017) | (Lee et al., 2017) | Korea | Asian | 44 | 55 | T (0.2 mg) plus S (5 or 10 mg) | T (0.2 mg) | 12 weeks |
| Yamaguchi (2011) | (Yamaguchi et al., 2011) | Japan | Asian | 210 | 215 | T (0.2 mg) plus S (2.5 or 5 mg) | T (0.2 mg) plus placebo | 12 weeks |
| Lee b Seung (2014) | (Lee et al., 2014) | Korea | Asian | 76 | 80 | T (0.2 mg) plus S (5 mg) | T (0.2 mg) | 12 weeks |
| Kaplan (2009) | (Kaplan et al., 2013) | USA | Caucasian | 202 | 195 | T (0.4 mg) plus S (5 mg) | T (0.4 mg) plus placebo | 4 weeks |
| Kerrebroeck a Van (2013) | (Van Kerrebroeck et al., 2013) | Europe | Caucasian | 180 | 179 | T (0.4 mg) plus S (3 or 6 or 9 mg) | T (0.4 mg) | 12 weeks |
| Ko (2014) | (Ko et al., 2014) | Korea | Asian | 94 | 93 | T (0.2 mg) plus S (5 mg) | T (0.2 mg) | 12 weeks |
| Marcus (2016) | (Drake et al., 2016) | UK | Caucasian | 339 | 327 | T (0.4 mg) plus S (6 mg) | T (0.4 mg) | 12 weeks |
| Chen (2019) | (Chen et al., 2018) | China | Asian | 53 | 53 | T (0.2 mg) plus S (5 mg) | T (0.2 mg) | 12 weeks |
| Kirill (2018) | (Kosilov et al., 2017) | Russian | Caucasian | 93 | 87 | T (0.2 mg) plus S (10 or 5 mg) | T (0.4 mg) plus placebo | 10 months |
T, Tamsulosin; S, solifenacin.
Superscript "a" and "b" were used to distinguish the studies with the similar first author names.